Acerus Pharmaceuticals Corporation announced the acceptance of the NATESTO® Spermatogenesis Study results for publication in an upcoming issue of the Journal of Urology. The single-institution, open-label, single-arm trial was conducted between November 2017 and September 2019 at the University of Miami'sDepartment of Urology. The study concluded that NATESTO® was found to be both effective in restoring hypogonadal men to normal testosterone levels, while also simultaneously improving both erectile function and quality of life. Importantly, gonadotropin hormones remained within normal ranges and semen parameters were preserved through 6 months of treatment in 95% of men. The study authors estimate that up to 16% of men being prescribed testosterone therapy (TTh) are under 39 years old. The most commonly prescribed testosterone therapies, injections and topical gels, can impair semen parameters and can cause azoospermia (absence of sperm in the semen) in up to 2/3rds of men. Therapies such as clomiphene citrate, a selective estrogen receptor modulator (SERM), are widely used off-label to preserve spermatogenesis while simultaneously increasing testosterone. Many of these off-label products can have several adverse reactions; therefore, identifying alternatives to increase testosterone in men without impacting gonadotropin levels and sperm parameters is paramount. The Phase IV clinical trial investigating the impact of nasally administered NATESTO® on restoration of testosterone and preservation of fertility parameters evaluated 44 subjects through 3 months, and 33 subjects through 6 months of treatment. Mean testosterone increased from 231 ng/dL to 652 ng/dL after 6 months of NATESTO® treatment. There was improvement across all domains of erectile function (based in IIEF-15), with particularly significant improvements in sexual desire and overall satisfaction. Additionally, sperm concentration, sperm motility, and total motile sperm count were maintained through 6 months of NATESTO® treatment.